ATE528410T1 - Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration - Google Patents

Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration

Info

Publication number
ATE528410T1
ATE528410T1 AT05851755T AT05851755T ATE528410T1 AT E528410 T1 ATE528410 T1 AT E528410T1 AT 05851755 T AT05851755 T AT 05851755T AT 05851755 T AT05851755 T AT 05851755T AT E528410 T1 ATE528410 T1 AT E528410T1
Authority
AT
Austria
Prior art keywords
macular degeneration
related macular
compositions
methods
amd
Prior art date
Application number
AT05851755T
Other languages
German (de)
English (en)
Inventor
Josephine Hoh
Robert Klein
Original Assignee
Univ Yale
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Univ Rockefeller filed Critical Univ Yale
Application granted granted Critical
Publication of ATE528410T1 publication Critical patent/ATE528410T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05851755T 2004-11-18 2005-11-18 Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration ATE528410T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62936304P 2004-11-18 2004-11-18
US64947905P 2005-02-02 2005-02-02
US67234605P 2005-04-18 2005-04-18
PCT/US2005/041664 WO2006062716A2 (en) 2004-11-18 2005-11-18 Methods and compositions for treating ocular disorders

Publications (1)

Publication Number Publication Date
ATE528410T1 true ATE528410T1 (de) 2011-10-15

Family

ID=36578383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851755T ATE528410T1 (de) 2004-11-18 2005-11-18 Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration

Country Status (14)

Country Link
US (3) US20090017029A1 (enExample)
EP (1) EP1836312B1 (enExample)
JP (2) JP2008520242A (enExample)
KR (1) KR101290621B1 (enExample)
CN (2) CN101142321B (enExample)
AT (1) ATE528410T1 (enExample)
AU (1) AU2005314461B2 (enExample)
BR (1) BRPI0518289A2 (enExample)
CA (1) CA2588270A1 (enExample)
CY (1) CY1112579T1 (enExample)
DK (1) DK1836312T3 (enExample)
ES (1) ES2375490T3 (enExample)
IL (1) IL183284A (enExample)
WO (1) WO2006062716A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE426043T1 (de) 2002-11-25 2009-04-15 Sequenom Inc Verfahren zur identifizierung des brustkrebsrisikos
DK1713503T3 (da) 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
EP2357257B1 (en) 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
JP5290772B2 (ja) * 2006-02-13 2013-09-18 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 補体調節遺伝子における変異体が加齢性黄斑変性症を予測する
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
NZ574046A (en) * 2006-07-13 2012-09-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
AU2016204271B2 (en) * 2006-07-13 2018-04-19 University Of Iowa Research Foundation Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
CN101173314B (zh) * 2006-10-18 2010-12-01 四川省医学科学院（四川省人民医院） 检测老年黄斑变性疾病的试剂盒
CN106084054A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
AU2008251943B2 (en) 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
JP5226256B2 (ja) * 2007-07-26 2013-07-03 ニプロ株式会社 加齢黄斑変性症の発症リスクの予測方法
CA2704809A1 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CN103333952B (zh) * 2008-11-05 2015-07-29 健泰科生物技术公司 年龄相关的黄斑变性中的遗传多态性
US20120115925A1 (en) * 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
EP2533797A1 (en) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Complement factor h for oxidative stress disease conditions
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
US8809517B2 (en) * 2010-06-01 2014-08-19 University Of Kentucky Research Foundation Method of inhibiting Alu RNA and therapeutic uses thereof
EP2585110A4 (en) 2010-06-22 2014-01-22 Univ Colorado Regents ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
FR2983212A1 (fr) * 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN102707068B (zh) * 2012-05-31 2015-03-18 北京大学 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CA2891673C (en) 2012-11-15 2025-10-07 Apellis Pharmaceuticals Inc Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
PL2968457T3 (pl) 2013-03-14 2018-12-31 Baxalta Incorporated Czynnik h do transplantacji
JP6484215B2 (ja) 2013-03-14 2019-03-13 バクスアルタ インコーポレイテッド 関節リウマチの治療のためのｈ因子
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
KR102131973B1 (ko) * 2013-12-30 2020-07-08 주식회사 케이티 개인 건강관리 방법 및 시스템
HUE050921T2 (hu) * 2014-02-26 2021-01-28 Allergan Inc C5 komplementkomponens antitestek
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
CN106018838A (zh) * 2015-11-01 2016-10-12 李倩 一种用于检测眼科疾病的试剂盒及其检测方法
CN114712497B (zh) * 2015-12-03 2024-03-22 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
KR102011182B1 (ko) * 2016-10-07 2019-08-16 단국대학교 천안캠퍼스 산학협력단 익상편 과발현 유전자 및 이의 용도
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP3824095A4 (en) * 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
US20220146530A1 (en) * 2019-03-07 2022-05-12 Reti Mark Co., Ltd. A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof
KR102333953B1 (ko) * 2020-07-10 2021-12-02 인제대학교 산학협력단 신규한 황반변성 진단용 유전자 마커
CN113293206A (zh) * 2021-07-23 2021-08-24 西安医臻生物医药科技有限公司 一种快速鉴别老年黄斑病变风险的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
NZ509797A (en) * 1998-07-10 2003-11-28 Univ Sydney Prophylactic treatments of neovascularisation in macular degeneration using a steroid
WO2001066800A2 (en) * 2000-03-07 2001-09-13 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
CN1466953A (zh) * 2003-01-15 2004-01-14 哈佛东方生物医药（云南）有限公司 预防治疗老年黄斑变性的复合制剂
EP2357257B1 (en) * 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration

Also Published As

Publication number Publication date
IL183284A (en) 2014-09-30
JP2012080900A (ja) 2012-04-26
CN102618644A (zh) 2012-08-01
AU2005314461B2 (en) 2012-02-02
HK1113690A1 (en) 2008-10-10
JP2008520242A (ja) 2008-06-19
CN101142321A (zh) 2008-03-12
IL183284A0 (en) 2007-09-20
US20090017029A1 (en) 2009-01-15
CN101142321B (zh) 2012-06-06
US20120135000A1 (en) 2012-05-31
ES2375490T3 (es) 2012-03-01
KR20070105969A (ko) 2007-10-31
CY1112579T1 (el) 2016-02-10
BRPI0518289A2 (pt) 2008-11-11
WO2006062716A2 (en) 2006-06-15
EP1836312B1 (en) 2011-10-12
WO2006062716A3 (en) 2006-10-05
CA2588270A1 (en) 2006-06-15
EP1836312A2 (en) 2007-09-26
KR101290621B1 (ko) 2013-07-29
US20140018306A1 (en) 2014-01-16
DK1836312T3 (da) 2012-03-12
AU2005314461A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
DE602005024850D1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
SG141418A1 (en) Method for the detection of gene transcripts in blood and uses thereof
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
WO2006084196A3 (en) Method for defining virtual patient populations
ATE478062T1 (de) Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
MX336835B (es) Metodos y composiciones para el diagnostico y tratamiento de la enfermedad autoinmune secundaria a esclerosis multiple.
WO2010054288A3 (en) Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs")
DE602006018035D1 (de) Verfahren und kit zur quantitativen bestimmung von small, dense ldl cholesterol
EP2189541A3 (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
DE602004029061D1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
EP1363528A4 (en) METHODS OF DIAGNOSING AND TREATING CARDIOPATHIES
EP3935190A4 (en) Reagents, methods and kits for identifying pregnant human beings at risk for placental bed disorder(s)
DE602006015221D1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
ATE501276T1 (de) Verfahren zur gliomdiagnose mit unterscheidung zwischen progressiven und de-novo-formen
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1836312

Country of ref document: EP